Sec Form 13G Filing - Vivo Capital IX, LLC filing for - 2025-11-14

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G



Comment for Type of Reporting Person:  The number represents 3,157,894 shares of common stock, par value $ 0.001 per share (the "Common Stock") of IO Biotech, Inc. (the "Issuer"), issuable upon exercise of certain warrants. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. Based on the sum of (i) 65,880,914 shares of Common Stock outstanding of the Issuer as of August 11, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on August 14, 2025, and (ii) 3,157,894 shares of Common Stock, issuable upon exercise of the warrants held of records by Vivo Opportunity Fund Holdings, L.P.


SCHEDULE 13G



Comment for Type of Reporting Person:  The number represents 3,157,894 shares of Common Stock of the Issuer, issuable upon exercise of certain warrants. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. Based on the sum of (i) 65,880,914 shares of Common Stock outstanding of the Issuer as of August 11, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025, and (ii) 3,157,894 shares of Common Stock, issuable upon exercise of the warrants held of records by Vivo Opportunity Fund Holdings, L.P.


SCHEDULE 13G


 
Vivo Capital IX, LLC
 
Signature:/s/ Frank Kung
Name/Title:Frank Kung/Managing Member
Date:11/14/2025
 
Vivo Capital Fund IX, L.P.
 
Signature:/s/ Frank Kung
Name/Title:Frank Kung/Managing Member of Vivo Capital IX, LLC, General Partner
Date:11/14/2025
 
Vivo Opportunity, LLC
 
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:11/14/2025
 
Vivo Opportunity Fund Holdings, L.P.
 
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member of Vivo Opportunity, LLC, General Partner
Date:11/14/2025
primary_doc.xml